Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Progenza
- Development stage
- Unknown
- Lead developer
- Cambium Bio
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intraarticular
01
Overview
Progenza is an allogeneic, "off-the-shelf" cell therapy candidate developed by Cambium Bio (formerly Cambium Medical Technologies and Regeneus) for the treatment of knee osteoarthritis. The product consists of a synergistic combination of allogeneic adipose-derived mesenchymal stem cells (MSCs) and their secretome, which contains a rich array of cytokines and growth factors. Administered via intra-articular injection, Progenza aims to reduce joint inflammation and promote tissue repair by modulating the immune response and inhibiting pro-inflammatory mediators such as tumor necrosis factor (TNF) and interleukin-1 (IL-1). The secretome component is designed to provide immediate anti-inflammatory relief, while the MSCs contribute to sustained therapeutic activity and cartilage protection. Progenza has been evaluated in Phase 1 clinical trials, demonstrating safety and potential efficacy in reducing pain and improving joint function in patients with osteoarthritis.
- Brand names
- Progenza
- Other names
- ProgenzaRG-01RG01RG 01
02
Targets
FGFR3 (Fibroblast growth factor receptor 3)IL-6R (Interleukin-6 receptor subunit alpha)TGFBR (TGF-beta receptor)MET (Mesenchymal-epithelial transition factor receptor)IL10 (Interleukin-10)
Beyond the preview
Go deeper on Progenza.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Progenza.